Literature DB >> 30747960

Antibiotics for Ceftriaxone-Resistant Gram-Negative Bacterial Bloodstream Infections.

Jesús Rodríguez-Baño1, Belén Gutiérrez-Gutiérrez1, Gunnar Kahlmeter2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30747960     DOI: 10.1001/jama.2018.19345

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  5 in total

1.  Piperacillin-tazobactam versus meropenem for treatment of bloodstream infections caused by third-generation cephalosporin-resistant Enterobacteriaceae: a study protocol for a non-inferiority open-label randomised controlled trial (PeterPen).

Authors:  Roni Bitterman; Fidi Koppel; Cristina Mussini; Yuval Geffen; Michal Chowers; Galia Rahav; Lior Nesher; Ronen Ben-Ami; Adi Turjeman; Maayan Huberman Samuel; Matthew P Cheng; Todd C Lee; Leonard Leibovici; Dafna Yahav; Mical Paul
Journal:  BMJ Open       Date:  2021-02-08       Impact factor: 2.692

2.  PRO: Carbapenems should be used for ALL infections caused by ceftriaxone-resistant Enterobacterales.

Authors:  David L Paterson; Burcu Isler; Patrick N A Harris
Journal:  JAC Antimicrob Resist       Date:  2021-02-24

3.  CON: Carbapenems are NOT necessary for all infections caused by ceftriaxone-resistant Enterobacterales.

Authors:  Jesús Rodríguez-Baño; Belén Gutiérrez-Gutiérrez; Alvaro Pascual
Journal:  JAC Antimicrob Resist       Date:  2021-02-24

Review 4.  Ventilator-associated pneumonia in adults: a narrative review.

Authors:  Laurent Papazian; Michael Klompas; Charles-Edouard Luyt
Journal:  Intensive Care Med       Date:  2020-03-10       Impact factor: 17.440

5.  Stewardship program on carbapenem prescriptions in a tertiary hospital for adults and children in France: a cohort study.

Authors:  Julie Poline; Martine Postaire; Perrine Parize; Benoit Pilmis; Emmanuelle Bille; Jean Ralph Zahar; Pierre Frange; Jérémie F Cohen; Olivier Lortholary; Julie Toubiana
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-01-03       Impact factor: 3.267

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.